Clinical trial
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03749018 is registered in ClinicalTrials.gov with David Bond, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
- Lead sponsor
- David Bond, MD
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- January 2, 2019
- Completion date
- December 31, 2026
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
aggressive non-hodgkin lymphoma, ann arbor stage i primary mediastinal (thymic) large b-cell cell lymphoma, ann arbor stage ii b-cell non-hodgkin lymphoma, ann arbor stage ii primary mediastinal (thymic) large b-cell cell lymphoma, ann arbor stage iii b-cell non-hodgkin lymphoma, ann arbor stage iii primary mediastinal (thymic) large b-cell cell lymphoma, ann arbor stage iv b-cell non-hodgkin lymphoma, ann arbor stage iv primary mediastinal (thymic) large b-cell cell lymphoma, diffuse large b-cell lymphoma, high grade b-cell lymphoma with myc and bcl2 and/or bcl6 rearrangements, high grade b-cell lymphoma, not otherwise specified, indolent non-hodgkin lymphoma, mediastinal b-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classic hodgkin lymphoma, transformed non-hodgkin lymphoma